1. Hsiao JL, Antaya RJ, Berger T, et al. Hidradenitis suppurative and concomitant pyoderma gangrenosum: a case series and literature review. Arch Dermatol . 2010;146:1265-1270.
2. Moschella S. Is there a role for infliximab in the current therapy of hidradenitis suppurativa? a report of three treated cases. Int J Dermatol . 2007;46:1287-1291.
3. Powell FC, Su WP, Perry HO. Pyoderma gangrenosum: classification and management. J Am Acad Dermatol. 1996;34:395-409.
4. Ah-Weng A, Langtry JAA, Velangi S, et al. Pyoderma gangrenosum associated with hidradenitis suppurativa. Clin Exp Dermatol . 2005;30:669-671.
5. Braun-Falco M, Kovnerystyy O, Lohse P, et al. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)—a new autoinflammatory syndrome distinct from PAPA syndrome. J Am Acad Dermatol . 2012;66:409-415.
6. Buckley DA, Rogers S. Cyclosporin-responsive hidradenitis suppurativa. J R Soc Med. 1995;88:289-290.
7. Shenefelt PD. Pyoderma gangrenosum associated with cystic acne and hidradenitis suppurativa controlled by adding minocycline and sulfasalazine to the treatment regimen. Cutis. 1996;57:315-319.
8. Raynor A, Askari AD. Behçet’s disease and treatment with colchicine. J Am Acad Dermatol. 1980;2:396-400.
9. Steinhoff JP, Cilursu A, Falasca GF, et al. A study of musculoskeletal manifestations in 12 patients with SAPHO syndrome. J Clin Rheumatol. 2002;8:13-22.
10. Rosner IA, Richter DE, Huettner TL, et al. Spondyloarthropathy associated with hidradenitis suppurative and acne conglobata. Ann Intern Med. 1982;97:520-525.
11. von den Driesch P. Pyoderma gangrenosum: a report of 44 cases with follow-up. Br J Dermatol. 1997;137:1000-1005.
12. Brooklyn TN, Dunnill MG, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomized, double-blind, placebo-controlled trial. Gut . 2006;55:505-509.
13. Ruocco E, Sangiulliano S, Gravina AG, et al. Pyoderma gangrenosum: an updated review. J Eur Acad Dermatol Venereol . 2009;23:1008-1017.
14. Mortimer P. Management of hidradenitis suppurativa. Clin Exp Dermatol . 2002;27:328.
15. Blanco R, Martinez-Taboada VM, Villa I, et al. Long-term successful adalimumab therapy in severe hidradenitis suppurativa. Arch Dermatol . 2009;145:580-584.
16. Rambhatla PV, Lim HW, Hamzavi I. A systematic review of treatment for hidradenitis suppurativa. Arch Dermatol . 2012;148:439-446.
17. Alecsandru D, Padilla B, Izquierdo JA, et al. Severe refractory hidradenitis suppurativa in an HIV-positive patient successfully treated with infliximab. Arch Dermatol . 2010;146:1343-1345.
18. Alexis A, Strober B. Off-label dermatologic uses of anti-TNF-a therapies. J Cutan Med Surg . 2006;9:296-301.
19. Grant A, Gonzalez T, Montgomery MO, et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol . 2010;62:205-217.
20. Fardet L, Dupuy A, Kerob D, et al. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients. J Am Acad Dermatol . 2007;56:624-628.
21. Usmani N, Clayton TH, Everett S, et al. Variable response of hidradenitis suppurativa to infliximab in four patients. Clin Exp Dermatol . 2007;32:204-205.
22. Kleinpenning MM, Langewouters AM, Van De Kerkhof PC, et al. Severe pyoderma gangrenosum unresponsive to etanercept and adalimumab. J Dermatolog Treat . 2011;22:261-265.
23. Wolbing F, Fierlbeck G, Hotzenecker W, et al. Septic shock after treatment of pyoderma gangrenosum with infliximab. Acta Dermato-Venereologica. 2009;89:93-94.
24. Shareef MS, Munro LR, Owen RG, et al. Progression of IgA gammopathy to myeloma following infliximab treatment for pyoderma gangrenosum. Clin Exp Dermatol. 2012;37:146-148.
